ProQR Therapeutics N.V.
PRQRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. At a $239.9M market cap, ProQR Therapeutics N.V. ranks as a micro-cap company within healthcare. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Market Cap
$239.9M
Beta
0.03
P/E (TTM)
—
P/E (Fwd)
-2.50
EPS (TTM)
$-0.50
EPS (Fwd)
$-0.68
ROE
-78.1%
ROA
-23.1%
Cash
$81.1M
Total Debt
$15.7M
Free CF
-$22.5M
52W Change
-24.8%
Annual Financials
Cash vs Debt
With $81.1M in cash and $15.7M in debt, PRQR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$22.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -78.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $3.6M (2022) to $15.9M (2025), reflecting a 343% increase over the period.
With a beta below 0.7, ProQR Therapeutics N.V. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ProQR Therapeutics N.V. and its sector.